Hyderabad-based

海得拉巴的

Natco Pharma

纳特科制药

has launched its generic

推出了其通用

semaglutide

司美格鲁肽

injection in India at a starting price of Rs 1,290 per month, marking one of the cheapest entries into the fast-growing GLP-1 diabetes therapy segment and significantly undercutting existing options in the market.

印度的注射剂起始价格为每月1290卢比，是快速增长的GLP-1糖尿病治疗领域中最便宜的药物之一，大大低于市场上现有的选择。

Also Read:

另请阅读：

The weight is over. This injectable fits the bill

体重问题结束了。这种注射剂正合适。

The company said it had received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market the drug, following a clinical comparison study.

该公司表示，继一项临床对比研究之后，已于2026年2月获得中央药品标准控制组织（CDSCO）批准生产和销售该药物。

Semaglutide is widely used for the treatment of adults with inadequately controlled

Semaglutide 广泛用于治疗控制不佳的成人患者

Type 2 diabetes

2型糖尿病

mellitus, typically prescribed alongside diet and exercise.

糖尿病，通常与饮食和运动一起处方。

Natco will roll out the drug in

纳科将推出该药物

multi-dose vial

多剂量瓶

formats under the brand names SEMANAT and SEMAFULL, with pricing starting at Rs 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants, and Rs 1,750 for the 8 mg/3 ml strength. The company also plans to introduce a pen-device version in April, priced between Rs 4,000 and Rs 4,500 per month depending on dosage..

以SEMANAT和SEMAFULL品牌名推出的格式，2毫克/1.5毫升和4毫克/3毫升变体的定价从每月1,290卢比起，8毫克/3毫升的定价为1,750卢比。公司还计划于四月推出一款笔式设备版本，根据剂量不同，每月售价在4,000至4,500卢比之间。

Live Events

现场活动

Also Read:

另请阅读：

Natco Pharma stock shows rounding bottom formation; should you buy the stock for long term?

Natco Pharma 股票呈现圆底形态；是否应该买入该股票进行长期投资？

The launch comes as the patent on semaglutide — the active ingredient in Novo Nordisk’s blockbuster drugs Ozempic and Wegovy — expires in India this week, ending the company’s exclusivity and opening the market to a wave of lower-cost generics. The expiry is expected to sharply reduce prices in a market where monthly therapy previously cost upwards of Rs 10,000, widening access in a country with one of the world’s largest diabetes and obesity burdens..

随着诺和诺德旗下重磅药物 Ozempic 和 Wegovy 的活性成分司美鲁肽的专利本周在印度到期，该公司的独家经营权也随之结束，市场将向一波低成本仿制药开放。专利到期预计将大幅降低市场价格，在此之前，每月治疗费用超过 10,000 卢比，而这一降价将扩大印度这一拥有全球最大糖尿病和肥胖负担国家的药物可及性。

Indian drugmakers have moved quickly to tap the opportunity, with more than 40 companies — including Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories and Lupin Limited — preparing to launch over 50 generic versions in the coming weeks. Companies are racing to gain early-mover advantage through partnerships, co-marketing deals and aggressive pricing strategies, intensifying competition in what is expected to become a multi-billion-dollar market.

印度制药企业迅速抓住了这一机遇，包括太阳制药工业公司、雷迪博士实验室和卢平有限公司在内的40多家公司正准备在未来几周内推出50多种仿制药版本。各公司正在通过合作伙伴关系、联合营销协议和激进的定价策略竞相争取早期优势，加剧了这个预计将成为一个价值数十亿美元市场的竞争。

Natco said it is the first to introduce semaglutide in multi-dose vial form in India, offering customised syringes and enabling broader distribution through co-marketing partnerships.

纳科表示，它是印度首家以多剂量小瓶形式引入司美鲁肽的公司，提供定制注射器，并通过共同营销合作伙伴关系实现更广泛的分销。

Highlighting the affordability angle, Natco said the vial-based therapy is about 70% cheaper than pen devices and nearly 90% less expensive than the innovator’s brand, a move expected to significantly improve patient access and long-term treatment adherence.

Natco 强调了其可负担性优势，称这种基于小瓶的疗法比笔式装置便宜约 70%，比原研品牌的价格低近 90%，这一举措预计将显著改善患者的用药可及性和长期治疗依从性。

Also Read:

另请阅读：

HC seeks Novo Nordisk's reply on Natco plea to revoke patent

高等法院要求诺和诺德就纳特科请求撤销专利作出回应

The launch comes as demand rises for GLP-1 therapies globally, with India emerging as a key growth market due to its large diabetic population. Natco said the lower pricing could help expand access to advanced diabetes care across the country.

随着全球对GLP-1类药物需求的增加，印度因庞大的糖尿病患者群体成为关键增长市场。纳特科公司表示，较低的价格有助于在全国范围内扩大获得先进糖尿病治疗的机会。

The company, which focuses on complex generics and specialty pharmaceuticals, operates nine manufacturing facilities and two R&D centres in India, supplying products to more than 50 global markets.

该公司专注于复杂的仿制药和特种药品，拥有九家生产工厂和两个研发中心，向 50 多个全球市场供应产品。

The country’s most definitive MSME stage returns on March 24 in New Delhi. Register now for the ET MSME Awards 2025

该国最权威的中小微企业舞台将于3月24日在新德里回归。立即注册参加2025年《经济时报》中小微企业奖。

Add

添加

as a Reliable and Trusted News Source

作为一个可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)